Southern Africa Enhances Early Warning Systems as Event-Based Surveillance Guidelines are Launched in Three Countries
Botswana, Namibia, and Zimbabwe were supported in developing their guidelines by the Africa Centres for Disease Control and Prevention (Africa CDC), in collaboration with the World Health Organization (WHO) and the United States Centers for Disease Control and Prevention (US CDC).
The Botswana Event-Based Surveillance Guidelines were launched on 24 June in Gaborone.
'By institutionalising a robust early warning system, the health sector will be empowered to detect signals of potential disease threats at their earliest stages,' said Dr Stephen Modise, MP, Minister of Health and Wellness.
Speaking on Dr Modise's behalf, Dr Rex Kealebile Segadimo, Acting Secretary for Specialised Health Care, said the launch of these guidelines marks a significant milestone in Botswana's efforts to strengthen its public health system.
'This will enable the country to assess risks with precision and respond in a science-based manner, preventing threats from escalating into full-blown crises.'
Dr Modise further stated: 'The institutionalisation of a robust early warning system will enable us to stay ahead of emerging health risks and respond effectively to protect the health and well-being of our citizens.'
Dr Lul Riek, the Africa CDC Regional Director for Southern Africa, reaffirmed his commitment to supporting Botswana and all AU Member States in operationalising these guidelines. This support will include capacity building, mentorship, digital tools, and regional coordination—as well as fostering peer learning and cross-border collaboration—recognising that no country can achieve health security in isolation.
With these guidelines in place, Botswana is now better equipped to respond quickly and effectively to emerging health threats, ultimately protecting the health and well-being of its citizens.
Officiating the launch in Windhoek, Namibia, also on 24 June, the country's Minister of Health and Social Services, Dr Esperance Luvindao, noted that EBS plays a critical role in addressing the increasing number of public health emergencies in the country. The new surveillance system is a timely intervention, as the country faces rising risks of communicable diseases such as malaria and cholera, increasingly influenced by climate-related factors.
She described the launch as a true demonstration of Namibia's commitment to being proactive in disease preparedness. 'Real-time detection of public health threats is essential to mitigate the impact of outbreaks, especially in the face of shifting disease patterns,' she said.
The Minister also called for a multifaceted approach to health security and emphasised the importance of establishing and prioritising National Public Health Institutes (NPHIs) to coordinate preparedness, response, and mitigation efforts.
The Ministry of Health and Child Care (MoHCC) in Zimbabwe launched its EBS Guidelines on 18 June in Harare.
'We are not gathered here merely to unveil a policy document,' said Dr Aspect Maunganidze, Secretary for Health and Child Care. 'We are here to affirm a national commitment—to declare that the health and safety of every Zimbabwean is our highest priority.'
He explained that the EBS guidelines represent a strategic shift from reactive to proactive preparedness, empowering health authorities to detect early warning signs of public health threats before they escalate.
Ms Batsirai Mbodza, Regional Programme Lead for Africa CDC, emphasised the critical importance of implementation.
'Guidelines alone will not stop outbreaks. The real impact lies in how well they are implemented,' she said. 'These tools must reach health workers in clinics, surveillance officers in the field, and community leaders, often the first to sense when something is amiss.'
On behalf of UNICEF, Mr Diop Daouda stressed the need for inclusivity in the country's surveillance systems.
'Surveillance systems must be inclusive, they must reach the most remote villages, informal settlements, and border communities,' he said, adding: 'They must consider gender dynamics, disability, and cultural norms. No signal should go unnoticed, because no life is dispensable.'
Distributed by APO Group on behalf of Africa Centres for Disease Control and Prevention (Africa CDC).
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Zawya
10 hours ago
- Zawya
Nigeria takes bold steps toward Hepatitis-free future with World Health Organization (WHO)'s support
The World Health Organization (WHO) has collaborated with the Government of Nigeria and hepatitis stakeholders to raise awareness and promote early diagnosis and treatment for World Hepatitis Day 2025. The global event, observed annually on 28 July, raises awareness about viral hepatitis- an inflammation of the liver that can lead to chronic liver disease and liver cancer. Hepatitis includes five types: A, B, C, D, and E. In the WHO African Region, over 70 million people suffer from chronic hepatitis B or C, but fewer than 10% are diagnosed or treated. Nigeria, with 325,000 new infections in 2022, ranks third globally in hepatitis prevalence. Chronic hepatitis B and C can lead to liver damage and cancer, even though they are preventable, treatable, and, in the case of hepatitis C, curable. This year's theme, 'Hepatitis: Let's Break It Down,' calls for action to remove financial, social, and systemic barriers, including stigma, that prevent hepatitis elimination and liver cancer prevention. For 2025 World Hepatitis Day, WHO joined the Ministry of Health and Social Welfare and its partners to mark the occasion with a ministerial press briefing at the Federal Secretariat, and launched a three-day hepatitis B screening, on the stop vaccinations for those who test negative, and linkage to treatment programme for those who test positive at the National Assembly Complex in Abuja. The event at the National Assembly in Abuja brought together health officials, legislators, and the public to address the issue of hepatitis. Addressing journalists at the press briefing, the Minister of Health and Social Welfare, Professor Mohammed Pate, represented by Dr Godwin Ntadom, Director Public Health Department, FMOH, reiterated Nigeria's commitment to combating hepatitis. He noted that the burden and cost of hepatitis treatment in the country is still very high and, as such, has a huge economic impact on the country and called for collective action in eliminating the disease. Dr Ntadom said, 'hepatitis costs Nigeria between ₦13.3 trillion and ₦17.9 trillion annually in direct and indirect costs. He also announced, 'Project 365,' a nationwide campaign aimed at eliminating Hepatitis C and halting Hepatitis B transmission by 2030. 'The project will support the ongoing efforts to eliminate mother-to-child transmission of HIV, hepatitis, and STIs, alongside expanding local pharmaceutical manufacturing through funding, the establishment of the Viral Elimination Fund, tax incentives, regulatory reforms, and legislative support. Nigeria must no longer hold the third-highest hepatitis burden globally. We have the science, we have the strategy, and we will act together, boldly and urgently, toward a hepatitis-free Nigeria, he said. WHO's Acting Representative in Nigeria, Dr Alex Gasasira, represented by Dr Mya Ngon, cluster lead for Universal Health Coverage (UHC) Communicable and Noncommunicable Diseases (NCDs) praised Nigeria's triple elimination initiative for HIV, hepatitis, and STIs, and emphasized the importance of reducing treatment costs, boosting local production, and expanding screening to achieve healthcare equity. WHO urges Nigeria and other nations to: • Ensure hepatitis B vaccination within 24 hours of birth; • Integrate hepatitis testing and treatment into primary healthcare services; • Address stigma and misinformation; • Secure sustainable domestic funding for hepatitis programs; and • Protect the rights of individuals living with hepatitis, especially in healthcare and employment. She reiterated WHO's commitment to supporting Nigeria's efforts to strengthen its health systems and expand access to affordable diagnostics, vaccines, and treatments. A beneficiary of the screening, Fash Yommie, 53, from Abuja, shared that he took the test to know his status. 'I took the test to know my status, and I am relieved to have tested negative. I now understand the importance of hepatitis prevention. I will start taking precautionary measures, such as avoiding sharing needles and ensuring proper hygiene with food and water, to protect myself and my loved ones from infection. I encourage everyone to get tested and vaccinated, as early detection is key to preventing this disease. "Early detection and vaccination are crucial in preventing the spread of hepatitis. Hepatitis B is transmitted through contact with infected blood or fluids, hepatitis C via blood-to-blood contact like sharing needles, and hepatitis A and E through contaminated food or water. Nigeria has enhanced hepatitis B prevention by adding the vaccine to the national schedule, supported by WHO, Gavi, UNICEF, and partners, to vaccinate all newborns and children and reduce early transmission. This year's activities reflect the broader goal of integrating hepatitis services into Nigeria's primary healthcare system, making screening and treatment more accessible to vulnerable populations. The National Assembly event is part of WHO's ongoing collaboration with Nigeria to achieve universal health coverage and align with the 2030 Global Health Agenda. Through national and local partnerships, WHO supports Nigeria in reducing the hepatitis burden and improving public health outcomes. The three-day screening serves as a reminder that hepatitis is preventable, and everyone has a role in raising awareness and preventing its spread. Distributed by APO Group on behalf of World Health Organization (WHO) - Nigeria.
Zawya
10 hours ago
- Zawya
Africa Centres for Disease Control and Prevention (Africa CDC) and European Commission Launch New Initiative to Strengthen Mpox Testing and Sequencing Across Africa
The Africa Centres for Disease Control and Prevention (Africa CDC) and the European Commission today announced the launch of the Partnership to Accelerate Mpox Testing and Sequencing in Africa (PAMTA), a landmark initiative to boost diagnostics and outbreak response capabilities in Mpox-affected African countries. Co-funded under the EU4Health 2024 Work Programme, PAMTA reflects the growing momentum of Africa–EU health cooperation and aims to reinforce the continent's resilience against current and future health threats. The initiative will accelerate testing, sequencing, capacity building, and local manufacturing efforts for mpox and other priority pathogens across Africa through a €9.4 million to Africa CDC and the African Society for Laboratory Medicine (ASLM), managed by the European Health and Digital Executive Agency (HaDEA). The project officially began on 1 June 2025 and will be implemented over three years. Africa CDC Director General, H.E. Dr Jean Kaseya, welcomed the initiative as a timely and strategic intervention to close the diagnostic gap for Mpox and other outbreaks in Africa. 'This partnership reflects our commitment to working with trusted partners to build agile and self-reliant public health systems across Africa. Together with the EU and our technical partners, we are setting a new benchmark for outbreak detection and response.' The PAMTA initiative focuses on four key objectives: scaling up Mpox testing with the goal of supporting over 150,000 tests across the continent; strengthening genomic sequencing capacity to track viral evolution and spread; building human resource capacity in molecular diagnostics, genomics, bioinformatics and data interpretation; and promoting the production and validation of locally developed testing kits within Africa. 'PAMTA marks a historic milestone as the first initiative jointly signed between the European Commission and Africa CDC,' said Deputy Head of DG HERA, Laurent Muschel. 'Building on HERA's earlier donation of Mpox vaccines, this action enables a critical next step: strengthening diagnostic capacities as part of a broader medical countermeasures approach. It reflects our shared commitment to reinforcing epidemic preparedness across Africa — from vaccines to diagnostics, from innovation to manufacturing. This action shows that, together, the African Union and the European Union can deliver tangible results to protect lives.' The launch of PAMTA builds on broader efforts by the EU and its partners to address the Mpox outbreak. By mid-2025, more than 600,000 vaccine doses had been delivered to African countries through HERA and Team Europe. Simultaneously, research initiatives such as MPX-RESPONSE and EDCTP3 continue to explore new therapeutic options, while the Africa Pathogen Genomics Initiative (PGI)—also funded through EU4Health—is enhancing public health laboratory networks and genomic surveillance across the continent through public private partnerships. PAMTA marks a significant milestone in EU–Africa collaboration for health resilience. By supporting comprehensive diagnostics and fostering local innovation, the initiative is helping to lay a strong foundation for Africa's long-term pandemic preparedness and response capabilities. Distributed by APO Group on behalf of Africa Centres for Disease Control and Prevention (Africa CDC).
Gulf Business
16 hours ago
- Gulf Business
UAE sets new standards for next-generation oral products
Credit: Getty Images In this interview, Alexandre Ghanem, Cluster Head of Middle East & North Africa (MENA) at BAT, discusses the significance of the new rules, how they align with global harm reduction efforts, and BAT's plans to launch a new portfolio in the UAE. Pictured: Alexandre Ghanem, Cluster Head of Middle East & North Africa (MENA) at BAT. What are BAT's plans for the UAE with this new regulatory framework in mind? The UAE's decision to issue regulatory requirements for tobacco-free oral nicotine pouches aligns with BAT's transformation and our vision of creating 'A Better Tomorrow'—a smokeless world driven by reducing the health impact of our business. Tobacco Harm Reduction (THR) as a policy encourages adult consumers who would otherwise continue to smoke to switch to lower-risk alternatives. Adult smokers and nicotine users in the UAE are progressive and open to innovative products. The UAE standard now provides access to high-quality alternatives, which is why BAT plans to introduce a new portfolio of tobacco-free oral nicotine pouches under the VELO brand in the market, in line with our THR ambitions. How significant is regulating tobacco-free oral nicotine pouches to harm reduction in the UAE? The UAE continues to lead in regulatory innovation. The Ministry of Industry and Advanced Technology's (MoIAT) decision to issue a technical standard for tobacco-free oral nicotine pouches reflects a strong commitment to public health and quality control. It is widely accepted that most harm from smoking comes from inhaling the smoke produced by burning tobacco—not from nicotine itself. Tobacco-free oral nicotine pouches, being smokeless and tobacco-free, present a reduced-risk profile when compared to combustible products, assuming a complete switch from smoking. How effective has the launch of BAT's tobacco-free nicotine pouches been elsewhere? Can that success be replicated in the UAE? Our tobacco-free nicotine pouches are currently available in over 40 countries, with 7.4 million adult consumers globally. VELO products are developed under rigorous stewardship and have been shown to contain 90–99 per cent fewer toxic chemicals compared to cigarette smoke. The broader category of oral nicotine pouches has contributed significantly to global public health by reducing smoking rates. Sweden is a notable example, where oral nicotine has largely replaced smoking over the past 70 years, resulting in the lowest smoking rate and lung cancer mortality rate in Europe—29.1 deaths per 100,000 compared to the EU average of 66.7 (2020 data). As of 2024, Sweden's smoking rate stands at 5.3 per cent, positioning it to achieve the WHO's 'smoke-free' status and putting the country 15 years ahead of the EU's 2040 target. Where do tobacco-free oral nicotine pouches fall on the risk continuum compared to cigarettes? Leading health bodies, including the US FDA, acknowledge that the main causes of smoking-related diseases are the harmful chemicals in tobacco smoke—not nicotine itself. In 2008, the WHO identified nine key toxicants in cigarette smoke. In VELO products, these are reduced by more than 99 per cent. While smokers may be addicted to nicotine, nicotine itself is not classified as a carcinogen. The Royal College of Physicians in London reinforces this, noting that the real danger lies in the smoke. If nicotine can be delivered in an effective and acceptable smokeless form, such as oral pouches, most—if not all—of the harm from smoking could potentially be avoided.
